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Non-invasive markers of airway inﬂammation
and remodeling in childhood asthma
Introduction
Bronchial asthma is deﬁned as a chronic inﬂam-
matory disease of the airways. The presence of
chronic inﬂammation is associated with bron-
chial obstruction and with structural changes of
the airways, i.e. bronchial remodeling (1). The
assessment of asthma control as well as
the deﬁnition of the severity of the disease by
the current guidelines are based only on symp-
toms, short-acting b2-agonists use, and on
measures of lung function (2). No inﬂammatory
parameters are presently taken into account
although often symptoms are not speciﬁc and
not closely related to the presence and severity of
airway inﬂammation (3).
Some interesting studies have been aimed to
deﬁne the inﬂammatory and immunologic com-
ponents of asthma in children (4, 5), however
relatively few data are available on the deﬁnition
of the biologic mechanisms underlying inﬂam-
mation and remodeling in these asthmatic
patients using non-invasive methods currently
available, such as exhaled nitric oxide (FeNO)
and induced sputum (6, 7). Some studies have
addressed the usefulness of FeNO and induced
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To evaluate the relationship between pro-inﬂammatory and pro-
remodeling mediators and severity and control of asthma in children,
the levels of IL-8, MMP-9, TIMP-1 in induced sputum supernatants,
the number of sputum eosinophils, as well as FeNO, were investigated
in 35 asthmatic children, 12 with intermittent (IA) and 23 with moderate
asthma (MA), and 9 controls (C). The patients with asthma were fol-
lowed for 1 yr and sputum was obtained twice during the follow-up.
Biomarker levels were correlated with the number of exacerbations. We
found that IL-8, MMP-9, TIMP-1 and the numbers of eosinophils in
induced sputum, as well as FeNO, were increased in children with IA
and MA in comparison to C. The ongoing inﬂammation was conﬁrmed
by increased nuclear p65 NF-jB subunit localization in sputum cells. In
MA, FeNO measurements, sputum eosinophils and IL-8 levels, posi-
tively correlated with the occurrence of disease exacerbations during a
1-yr follow-up. According to FeNO, sputum eosinophils and IL-8
sputum concentrations, and the number of exacerbations, two distinct
phenotypes of MA were identiﬁed. This study shows that the presence
of bronchial inﬂammation is detectable in the airways of some IA, as
well as in the airways of MA, despite the regular ICS treatment. This
study also proposes the need to perform large prospective studies to
conﬁrm the importance of measuring speciﬁc biomarkers in induced
sputum, concomitantly to FeNO analyses, to assess sub-clinical airway
inﬂammation and disease control in children with asthma.
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sputum in detecting airway inﬂammation in
asthmatic patients (7–10). FeNO is associated
to respiratory symptoms, lung function, bron-
chial responsiveness, blood eosinophilia and it
has been already demonstrated, both in adults
and children, that a strategy based on the
measurement of FeNO or sputum eosinophilia
allows to avoid asthma exacerbations, to reduce
inhaled corticosteroids requirement and to
improve airway hyperresponsiveness (11, 12).
Most of the mediators related to asthma
inﬂammation and remodeling, including Inter-
leukin-8 (IL-8), Metalloproteinases (MMPs), and
inhibitors of metalloproteinase (TIMPs), can be
measured in the supernatant of induced sputum
(13, 14). IL-8, has been shown to play an
important role in adult and childhood asthma,
and despite continuous long-term treatment with
systemic and inhaled glucocorticoids (GC), high
levels of IL-8 are synthesized by airway cells and
peripheral blood mononuclear cells (PBMC) of
severe uncontrolled asthmatics (15, 16), and
moderate persistent asthmatic children where
IL-8 is correlated with the occurrence of exacer-
bations (6). MMPs and TIMPs, are important
mediators of inﬂammation, cytokine activation,
and tissue remodeling. The balance between
MMPs and the TIMPs plays an important role
in the breakdown and deposition of extra-cellular
matrix (ECM) in the airways wall representing
an important cause of airﬂow limitation in
asthma (17). Although the major source of
MMP-9 in the lung is represented by macro-
phages, followed by neutrophils and epithelial
cells, high levels of active MMP-9 have been also
demonstrated to be released by eosinophils in
asthmatic airway inﬂammation (18) and in
eosinophilic asthma (19). IL-8 has been shown
to induce the release of MMP-9 from neutroph-
ils, and in turn MMP-9 can increase IL-8 potency
(20). In this context, it was observed that the
transcriptional factor NF-jB, which plays a role
in the persistence of inﬂammation (21), regulates
IL-8 (22) and MMP-9 (23) gene expression and is
in part responsible (via IKK/NF-jB pathway) of
the TIMP-1 gene regulation (24).
We hypothesized that markers of inﬂamma-
tion or remodeling in induced sputum may
mirror asthma severity and control in asthmatic
children. For this reason, we undertook a pro-
spective follow-up study in children with inter-
mittent asthma (IA), and moderate asthma
(MA), who were clinically and functionally well
controlled and were receiving medium doses of
inhaled corticosteroids and long-acting b2 agon-
ists. We aimed to investigate the inﬂammatory
status of these patients using non-invasive
methods including induced sputum biomarkers
measurements (number of eosinophils, IL-8,
MMP-9, TIMP-1 and p65 NF-jB subunit),
concomitantly with FeNO. Finally, we evaluated
whether these biomarkers were correlated with
the development of disease exacerbations
throughout an 1-yr follow-up period of time.
Materials and methods
Subjects
Forty-three asthmatics (6–14 yr, mean s.d.:
9.2 ± 2.5) were recruited from the outpatient
clinic of the children hospital ARNAS in
Palermo, Italy. The diagnosis of asthma and
the assessment of its severity and control were
done at study entry according to Global Initia-
tive for Asthma (25). Only 35 of 43 asthmatic
children were able to obtain suitable sputum
samples at visit 1 and to be included in the study.
All these included subjects were able to perform
induced sputum at visit 3, either on the scheduled
day of visit 3 or within 1 wk from it.
Twelve children had intermittent asthma, trea-
ted with short-acting b2agonists on demand dur-
ing the last 3 months; 23 children had moderate
asthma treatedwith ﬂuticasone propionate 250 lg
[inhaler device Diskus (GlaxoSmithKline, Brent-
ford, UK)] plus Salmeterol 50 lg bid, for at least
3 months. This high dose of Fluticasone was used
to stabilize these patients and to let them have a
controlleddisease, at least considering the clinical
and functional parameters. The control group
consisted of nine healthy children. Throughout a
longitudinal 1-yr follow-up study, the visits 1, 2, 3
and 4 were scheduled every 4 months. The study
was approved by the Institutional Ethical Com-
mittee. All parents of the children signed a written
informed consent.
Clinical assessment and compliance of patients
Pulmonary function tests were performed as
recommended by the American Thoracic Society
(26). Forced expiratory volume in 1 s (FEV1),
forced vital capacity (FVC) were measured
according to ATS guidelines and the best of three
technically acceptable and reproducible maneu-
vers was retained (26). Atopic status was assessed
by skin-prick tests (27) to aeroallergens commonly
present in theMediterranean area, and total serum
IgE measurements. The compliance to treatment
was assessed by checking the inhalation technique
at each visit. We also measured basal plasma
cortisol concentrations at 8:00 amby electrochem-
iluminescence twice (visits 1 and 4). Results were
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expressed in nanomolar concentrations, and
adherence to inhaled corticosteroids was consid-
ered satisfactory if cortisol was less than 100 nm
(28, 29). To accurately monitor the patients
symptoms, at the beginning of the study parents
were provided with cell phone numbers of phisi-
cianswhowere on call always reachable 24 h a day
for the entire follow-up period. Parents were
accurately instructed to refer to physicians about
any symptoms occurred. When symptoms possi-
bly related to putative exacerbations occurred, on
the basis of physicians evaluation, patients under-
went unscheduled visits on the same or on the
following day, in order to verify the eﬀective
presence and to classify and treat the exacerba-
tions. Asthma exacerbations were deﬁned as
increasing symptoms and signs of asthma (cough-
ing, wheezing, shortness of breath) unresponsive
to the patients routine asthma medication and
requiring an unscheduled visit. Mild and severe
exacerbations were diﬀerentiated according to the
Formoterol and Corticosteroids Establishing
Therapy study (30). Severe exacerbations were
treated with a short course of oral steroids (1 mg/
kg of prednisolone for 2–5 days). The number of
mild and severe exacerbations occurred during the
follow-up period was recorded. Moderate asth-
matic children were divided into two subgroups
on the basis of the frequency of severe exacerba-
tions (31).
Nitric oxide measurement
FeNO was determined by a chemiluminescence
analyzer connected to a computerized system
(NIOX; Aerocrine AB, Solna, Sweden), and
measured in triplicate after fast inhalation
maneuvers to total lung capacity, at a constant
ﬂow rate of 50 ml/s (32). The mean of three
measures was retained for the analysis.
Sputum induction
Each subject underwent spirometry before the
beginning of the procedure. If FEV1 was over
75% of predicted at baseline and the child had
not used a short-acting b2-agonist within the last
6 h, we performed the procedure without pre-
medication. Patients were exposed to an aerosol
of 4% hypertonic saline solution, monitoring the
assessment of bronchial reactivity, as described
elsewhere (33).
Sputum processing
Sputum processing was performed according
to the methods of Hargreave et al. with minor
modiﬁcations (34). The cells obtained from in-
duced sputum were then cytocentrifuged (Cyto-
spin 2; Shandon Instruments, Runcorn, UK) and
stained with Diﬀ-Quick (Merz-Dade, Dudingen,
Switzerland (CH)). Slides were read blindly by
two independent investigators and diﬀerential
cell counts were expressed as a percentage of 400
cells.
Measurement of IL-8, MMP-9, TIMP-1
Evaluation of IL-8, MMP-9, and TIMP-1 con-
centrations in induced sputum supernatants was
assessed using commercially available speciﬁc
enzyme-linked immunoadsorbent assay kits
(R&D Systems, UK; Biotrack, Amersham Inter-
national plc, UK) according to the manufac-
turers instructions.
Immunocytochemistry analysis
To further characterize the ongoing bronchial
inﬂammation in both groups of asthmatics, we
performed immunocytochemical analyses in spu-
tum cells to determine the subcellular distribu-
tion of p65 NF-jB subunit. After thawing,
immunoreactivity for p65 NF-jB subunit, was
evaluated using the labeled streptavidin–biotin
method (Alkaline phosphatase Rabbit/Mouse/
Goat; Universal LSAB + kit; Dako, Glostrup,
Denmark), as previously described (21). The cell
identiﬁcation was based on cell morphology
under light microscopy (·400 ﬁnal magniﬁca-
tion), carefully referring to the cell type distribu-
tion in corresponding Diﬀ-Quick-stained slides.
p65 localization was expressed as percentage of
sputum cells showing a p65 nuclear staining.
Goat polyclonal anti-p65 NF-kB subunit (Santa
Cruz Biotechnology, Santa Cruz, California) was
diluted 1:20.
Study design
After 1 month run-in period, during which FEV1
before and after broncho-dilation (400 lg of
salbutamol) was assessed, patients attended the
outpatient clinic (visit 1) and underwent clinical
assessment (pre- and postbronchodilator FEV1)
after 4 (visit 2), 8 (visit 3) and 12 (visit 4) months
by the same physician (S.L.G) (Fig. 1). In
patients with an upper respiratory tract infection,
follow-up visits were postponed for 2 wk. Bio-
markers and FeNO levels were measured at visit
1 and at visit 3. Sputum eosinophilia, IL-8,
MMP-9, and TIMP-1 sputum concentrations
were measured in nine controls (C), 12 IA and
23 MA children. p65 nuclear localization was
Gagliardo et al.
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evaluated in group subsets, owing to limitation in
the amount of sputum cells recovered, in 6 out of
9 C, 8 out of 12 IA and 12 out of 23 MA children.
Statistical analysis
As variables were normally distributed, analysis
of variance (anova) was used for between-group
comparisons with Bonferronis correction for
multiple comparisons. Correlations were ana-
lyzed by linear regression analysis and multiple
linear regression analysis model.
Results
Demographic and functional characteristics of patients
The demographic and functional characteristics
of patients are reported in Table 1. No statisti-
cally signiﬁcant diﬀerences were found among
the three study groups in terms of FEV1 values at
all visits indicating that, on the basis of this
parameter, the asthmatic patients were function-
ally under control. We observed a signiﬁcant
FEV1/FVC decline in MA in comparison with C,
and in MA in comparison with IA at all visits. In
Visit 2: Visit 4:Visit  3:
Short-acting β2 agonists on demand
Visit 1:
4 months
Functional 
assessment
PFTs
compliance
Functional 
assessment
PFTs
compliance
cortisol 
Evaluation of 
severity/control
PFTs
FeNO
induced sputum
compliance
4 months 4 months
Evaluation of 
atopic status (SPT, 
sIgE), 
severity/control
PFTs; FeNO
induced sputum
compliance
cortisol 
Run-in
4 weeks
Moderate asthma Moderate asthma Moderate asthma
Fluticasone propionate 250 µg (inhaler device Diskus [GlaxoSmithKline, UK]) plus Salmeterol 50 µg bid
Intermittent asthma Intermittent asthma Intermittent asthma
Fig. 1. Flow chart of the study.
Table 1. Demographic, functional and cellular characteristics of subjects
Controls
Intermittent Moderate p-value
Asthma Asthma C/IA C/MA IA/MA
Number 9 12 23
Sex, M/F 6/3 8/4 15/8
Age 10 (9–10) 9 (8–10) 11.5 (10–12) NS NS NS
Total IgE (KU) 20 (15–20) 522 (308–857) 536 (387–770) p < 0.002 p < 0.001 NS
FEV1 (%) visit1 101 (100–103) 98 (94.5–104) 92 (89–96) NS NS NS
FEV1 (%) visit2 105 (100–110) 97 (92.5–102) 92 (87–98) NS NS NS
FEV1 (%) visit3 100 (100–102) 97 (92–100) 87 (78–94) NS NS NS
FEV1 (%) visit4 102 (100–106) 100 (89–104) 88 (84–94) NS NS NS
FEV1/FVC (%) vis1 100 (98.5–105) 94 (86–109) 83 (75–86) NS p < 0.0001 p = 0.0005
FEV1/FVC (%) vis2 103 (102–107) 92 (89–99) 87.5 (84–91) p = 0.01 p < 0.0001 p = 0.01
FEV1/FVC (%) vis3 100 (100–106) 93 (90–98) 85 (81–88) NS p < 0.0001 p = 0.002
FEV1/FVC (%) vis4 105 (100–106.5) 92 (89–99) 85 (80–89) p = 0.01 p < 0.0001 p = 0.002
FeNO visit1 8 (6–10) 18 (13–36) 22 (16–30) p = 0.0085 p = 0.013 NS
FeNO visit3 9 (7–11) 19.5 (13.5–26) 22.5 (14–30) p = 0.0066 p = 0.0023 NS
Sputum eosinophils visit1 0 5.75 (3–8) 4 (3–9) p = 0.0015 p = 0.0026 NS
Sputum eosinophils visit3 0.1 (0–0.5) 4.9 (3–7) 4.5 (3.5–7) p = 0.0033 p = 0.0036 NS
Asthma duration, yr NA 4 (3.25–6) 6 (4.25–6.75) NS
Total exacerbations 0 2 (2–3) 3 (2–4) p = 0.01
Severe exacerbations 0 1 (0–0) 2 (1–2.5) p < 0.0001
Cortisol (nm) 346 (215–458) 194 (170–225) 66 (58–95) p < 0.001 p < 0.0001 p < 0.004
Cortisol (nm) 342 (215–447) 195 (170–225) 69 (56–95) p < 0.002 p < 0.0001 p < 0.004
Results are expressed as median and (25–75 percentiles).
Cortisol levels at study entry.
Cortisol levels at the end of the follow-up period (12 months).
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IA a signiﬁcant FEV1/FVC decline in compari-
son to C was observed only at visits 2 and 4
(Table 1). In IA 25 exacerbations occurred (mean
2.1 exacerbations per patient), 24 of which mild
and 1 severe. In MA 73 exacerbations occurred
(mean 3 exacerbations per patient), 43 of which
mild and 30 severe.
FeNO and eosinophil number measurements
The levels of FeNO and the number of sputum
eosinophils were signiﬁcantly increased in IA and
MA in comparison with C at both visits 1 and 3,
whilst no signiﬁcant diﬀerences were detected
between the two groups of asthmatics (Table 1).
Detection of IL-8, MMP-9, TIMP-1
Wemeasured the concentrations of IL-8,MMP-9,
and TIMP-1 in the induced sputum supernatants
recovered from the three groups of subjects at
visits 1 and 3. The concentrations of IL-8 (Fig. 2),
MMP-9 and TIMP-1 (Fig. 3, a–b) were signiﬁ-
cantly increased in the two groups of asthmatics
when compared with controls at both visits 1 and
3.No signiﬁcant diﬀerences were detected in terms
of MMP-9/TIMP-1 molar ratio at both visits 1
and 3 among the three study groups (Fig. 3c). No
signiﬁcant diﬀerences were present comparing the
levels of each speciﬁc mediator at visit 1 and 3
(Figs 2 and 3).
Total and differential cell counts in induced sputum samples
The percentage of eosinophils was signiﬁcantly
higher in IA and MA than in C (p < 0.0005)
(Table 2). The IA andMA also had a signiﬁcantly
increased percentage of neutrophils and a signif-
icantly decreased percentage of macrophages
when compared with C (Table 2). The median
viability of the cells obtained from induced sputum
samples was 78% (25 to 75 percentiles: 70 to 85) in
C and 72% (25 to 75 percentiles: 65 to 80) in
asthmatic children.
Subcellular distribution of p65 NF-jB subunit
The percentage of induced sputum cells with a
p65 nuclear staining (p65 localization was
expressed as percentage of sputum cells showing
a p65 nuclear staining) was signiﬁcantly higher in
IA and MA than in C (p < 0.0005) (Table 3).
The percentage of macrophages, eosinophils
and neutrophils of sputum cells with a positive
p65 nuclear staining was signiﬁcantly higher in
IA and MA than in C, at both visits 1 and 3. No
diﬀerences were detected between the two groups
of asthmatic patients (Table 3).
Correlations
IL-8 sputum concentrations positively correlated
with MMP-9 and with TIMP-1 (p < 0.0001,
VISIT 3VISIT 1
2000 p < 0.0001
NS
NS
p < 0.0001
800
1200
1600 p = 0.002 p = 0.0001
0
400I
L-
8 
(pg
/m
l)
Control Intermittent
asthma
Moderate
asthma
Control Intermittent
asthma
Moderate
asthma
Fig. 2. Concentrations of interleukin-8 (IL-8) in sputum
supernatants of intermittent and moderate asthmatic chil-
dren and controls measured at visit 1 and visit 3. Individual
data are shown. Horizontal lines represent the median.
1000
VISIT 3VISIT 1
p = 0.0089
p = 0.013
p = 0.0079
NS
200
400
600
800 p = 0.011
0
p = 0.015 p = 0.007
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M
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(ng
/m
l)
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M
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1 
(ng
/m
l)
1000
1500
2000 p < 0.0001 p < 0.0001
0
500
7 NS
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2
3
4
5
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NS NS
0
1
Control Intermittent
asthma
Moderate
asthma
Control Intermittent
asthma
Moderate
asthma
M
M
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9/
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M
P-
1
m
o
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(b)
(c)
Fig. 3. Concentrations of metalloproteinase-9 (MMP-9)
(a), and tissue inhibitor metalloproteinase-1 (TIMP-1) (b) in
sputum supernatants of intermittent and moderate asth-
matic children and controls, measured at visit 1 and visit 3.
(c) MMP-9/TIMP-1 molar ratio in sputum samples of the
three study groups. Individual data are shown. Horizontal
lines represent the median.
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R2 = 0.66; p = 0.004, R2 = 0.4, respectively) in
MA. In this group of subjects, a positive correla-
tion was also present between the number of
sputum eosinophils and MMP-9 and TIMP-1
(p = 0.04, R2 = 0.25; p = 0.01, R2 = 0.3,
respectively).
The number of severe exacerbations occurred
in MA during the follow-up signiﬁcantly and
positively correlated with the levels of FeNO
(Fig. 4a), the number of eosinophils (Fig. 4b),
and the sputum concentrations of IL-8 at both
visits 1 (Fig. 4c) and 3 (data not shown). When a
multiple linear regression analysis was performed
between severe exacerbations as dependent
variable and FeNO, eosinophils and IL-8 as
independent variables, the R2 value showed a
marked increase (0.79) compared with single
linear regressions. On the basis of the number of
severe exacerbations occurred during the follow-
up, it was possible to identify two distinct
subgroups of patients with MA classiﬁed as
frequent exacerbators (‡2 exacerbations,
n = 10) and infrequent exacerbators (0 or <2
exacerbations, n = 13). The FeNO levels
(Fig. 4d), the number of sputum eosinophils
(Fig. 4e) and the IL-8 sputum concentrations
(Fig. 4f) measured in the frequent exacerbators
were signiﬁcantly higher than in the infrequent
exacerbators. No signiﬁcant correlation was
found between MMP-9, TIMP-1, and the
MMP-9/TIMP-1 molar ratio and the number of
severe exacerbations.
The number of sputum eosinophils (data not
shown), and IL-8 concentrations (Fig. 5a) pos-
itively correlated with the asthma duration
(p = 0.04, R2 = 0.25; p = 0.01, R2 = 0.25,
respectively), while IL-8 concentrations inver-
sely correlated with FEV1/FVC (p = 0.01,
R2 =0.36) (Fig. 5b) in MA. In addition, when
IA and MA were grouped together, the number
of total exacerbations, regardless severity, at
both visits 1 and 3, signiﬁcantly correlated with
sputum eosinophilia (p = 0.03; R2 = 0.4;
p = 0.04; R2 = 0.36, respectively), and IL-8
levels (p = 0.01; R2 = 0.43; p = 0.02; R2 =
0.4, respectively), but not with FeNO levels
(data not shown). No signiﬁcant correla-
tions were found between total number of
exacerbations and MMP-9, TIMP-1, and
MMP-9/TIMP-1 molar ratio. MMP-9 posi-
tively correlated with IL-8 levels (p < 0.0001,
R2 = 0.46).
Table 2. Total and differential count of cells from induced sputum
Control subjects Intermittent asthma Moderate asthma p-value
vis 1 vis 3 vis1 vis 3 vis 1 vis 3
C/IA C/MA IA/MA
vis 1 vis 3 vis 1 vis 3 vis 1 vis 3
Total cell counts (106 cells/ml) 0.8 (0.5–1.5) 0.7 (0.4–1.2) 1.5 (0.8–1.9) 1.1 (0.8–1.7) 1.2 (0.6–1.8) 1 (0.7–2) NS NS NS NS NS NS
Squamous cells (%) 3 (2–5) 3.5 (1.5–4.5) 2 (1–4) 1.5 (1–2.5) 2 (0–3) 1.5 (1–2.75) NS NS NS NS NS NS
Macrophages (%) 91 (90–95) 89.5 (89–95) 56.5 (49.5–70.6) 54 (50–71) 52.5 (25–63) 49.3 (21–60) ** ** ** ** NS NS
Eosinophils (%) 0 0.1 (0–0.5) 5.75 (3–8) 4.9 (3–7) 4 (3–9) 4.5 (3.5–7) ** ** ** ** NS NS
Neutrophils (%) 9 (5–11) 10 (5–13) 33.5 (6–36) 35.5 (16–45) 40 (12–61) 42 (6.75–56.75) * * ** ** NS *
Lymphocytes (%) 0 (0–0.5) 0 (0–0.8) 3.5 (1–3) 4 (2.1–6) 2.5 (1.5–4.5) 3 (2–4.5) NS * NS * NS NS
Epithelial cells (%) 0 (0–2.6) 0.5 (0–1.8) 0.5 (0–2) 1.5 (1–2) 1 (0–1.8) 1.2 (0–2) NS NS NS NS NS NS
Results are expressed as median (25–75 percentiles) of positive cells with respect to total cell counts.
*p < 0.005; **p < 0.0005; NS, not significant.
Table 3. Subcellular distribution of p65 NF-jB subunit by different cell types
Control subjects Intermittent asthma Moderate asthma p-value
vis 1 vis 3 vis1 vis 3 vis 1 vis 3
C/IA C/MA IA/MA
vis 1 vis 3 vis 1 vis 3 vis 1 vis 3
Total cells 2 (0–2.5) 2.3 (0–4) 54 (40–68) 59 (39–77) 60 (55–67) 58 (50–72) ** ** ** ** NS NS
Macrophages (%) 1.5 (0–2.5) 1 (0–1.75) 42 (38–45) 44 (40–51) 39 (30–50) 40 (33–49) ** ** ** ** NS NS
Eosinophils (%) 0 (0–0) 0 (0–0) 5 (3–8) 6.5 (2–10) 7 (5–9) 6.1 (4.5–8.5) ** ** ** ** NS NS
Neutrophils (%) 1 (0–2) 0.5 (0–1.75) 7 (6–11) 9 (6–12) 13 (9–15) 10 (7.5–14.5) ** ** ** ** NS NS
Lymphocytes (%) 0 (0–0) 0 (0–0.5) 1 (0–2) 1.2 (0.75–1.75) 1 (0–1.5) 2 (0–2.75) NS * NS * NS NS
Results are expressed as median (25–75 percentiles) of sputum cells with a p65 nuclear staining with respect to total cell counts.
*p < 0.005; **p < 0.0005; NS, not significant.
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Discussion
This study shows that the levels of several
biomarkers, including IL-8, MMP-9, TIMP-1,
number of eosinophils in induced sputum as well
as the levels of FeNO, are increased in children
with IA and MA as compared to C and that,
according to the levels of FeNO, number of
eosinophils, and IL-8 sputum concentrations,
two diﬀerent phenotypes of MA children can be
identiﬁed. These three latter markers correlate, in
MA, with the occurrence of disease exacer-
bations during a 1-yr follow-up period of time.
Treatment with ICS reduces FeNO by a direct
eﬀect on transcription of inducibile NO synthase
(35, 36) and, accordingly, FeNO has been pro-
posed as a sensitive non-invasive and reproduc-
ible marker of asthma activity that well correlates
with eosinophilic airway inﬂammation (37).
These ﬁndings suggest the possibility to use this
methodology in children to monitor the eﬃcacy
of the therapy on this speciﬁc parameter,
although recent studies showed that a therapy
regimen aimed to lowering FeNO in children
with asthma improved parameters of small air-
ways function but was not able to improve
clinical markers of asthma control (38). In this
context, we observed increased levels of FeNO
and sputum eosinophils in children with IA and
MA when compared with C while no signiﬁcant
diﬀerences were observed between both groups
of asthmatics during the 1-yr follow-up. Since it
has been demonstrated a heterogeneity of FeNO
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response to ICS (39) and since FeNO indicates
the severity and the control of childhood asthma
(40) the observed absence of a signiﬁcant diﬀer-
ence in oral FeNO between children with IA and
MA demonstrates that, despite the use of ICSs,
increased levels of oxidative stress markers, as
well as elevated eosinophils levels, persist in some
of these patients. Our ﬁndings that FeNO is
increased in a subgroup of MA patients conﬁrm
previous observations and extend them providing
new information on the usefulness of the use of
this marker in monitoring bronchial inﬂamma-
tion in asthma. Moreover, these ﬁndings support
the concept of the presence of diﬀerent pheno-
types of asthmatic patients detectable using non-
invasive methods including FeNO measurement.
IL-8 has been shown to play an important role
in the airways and in the systemic circulation of
both adulthood (16, 41), and childhood asthma
(6). High levels of IL-8 are synthesized from
PBMC of adult severe asthmatics (16), and
moderate persistent asthmatic children with sig-
niﬁcant diﬀerences when compared with inter-
mittent asthmatic children (6). An increase in the
expression of IL-8 was observed in the airway
mucosa of adult moderate-to-severe asthmatics
(41) as well as in the induced sputum superna-
tants of adult severe asthmatics showing an
elevated grade of neutrophilia (15) despite these
patients were receiving ICS therapy (41). In
addition, increased levels of IL-8 were observed
in induced sputum (42) of children with acute
asthma. In this context there were not clear
evidences about the eﬀects of ICS on the reduc-
tion of the levels of IL-8 in the airways of
asthmatic children. The present study extends
these ﬁndings at bronchial levels of IA and MA
children showing increased levels of IL-8 in
induced sputum supernatants when compared
with C. Although no signiﬁcant diﬀerences were
observed between IA and MA children during
the follow-up, we observed the presence of two
sub-groups of MA children: one showing a
reduction of IL-8 levels and another group
showing the presence of high levels of IL-8
suggesting the presence of bronchial inﬂamma-
tion despite the regular ICS treatment. These
observations support the concept of heterogene-
ity of bronchial asthma in MA children (6, 39)
and, once again, suggest the presence of diﬀerent
phenotypes of MA children.
Airway remodeling, traditionally referred to
the advanced steps of the disease (14), has been
shown to be present very early in the course of
childhood asthma (43). For this reason, it is
important to assess the relationships between
airway inﬂammation and remodeling and the
clinical spectrum of asthma severity in children.
We investigated MMP-9 and TIMP-1 in induced
sputum of asthmatic children and we found that
MMP-9 and TIMP-1 are signiﬁcantly increased
in both IA and MA in comparison with C at both
visits 1 and 3 while no diﬀerences were present
between IA and MA children. We did not ﬁnd
any signiﬁcant reduction of MMP-9/TIMP-1
molar ratio in these patients in comparison to
C, although in adult asthmatic patients the
MMP-9/TIMP-1 molar ratio is lower than in
control subjects, suggesting a trend toward
ﬁbrosis due to the existence of a protease–
antiprotease imbalance (14). The absolute con-
centration of TIMP-1, and not its molar ratio
with MMP-9, has been shown to be associated
with persistent wheezing in atopic preschool
children (44). Consistently, in our asthmatic
children the observed increased concentrations
of MMP-9 and TIMP-1 suggests that some pro-
remodeling mediators are present at least in a
subgroup of children although in the absence of a
protease–antiprotease imbalance. These ﬁndings
suggest that the remodeling process in some
children might be already initiated at the early
steps of the disease, although the eﬀects are not
yet deﬁned.
IL-8 promotes neutrophil and eosinophil inﬁl-
tration in the lung (45), leading to chronic
inﬂammation. MMP-9 is released by macrophag-
es, epithelial cells and eosinophils, and TIMP-1 is
the major tissue inhibitor secreted in association
with MMP-9. Consistently with this, it has
already been found a close relationship between
levels of IL-8 and MMP-9 in sputum of adult
asthmatics as well as a deﬁciency of antiproteases
mechanisms in the same patients (19). In addition,
it has been demonstrated that IL-8 is a substrate
for activated MMP-9 and the resultant MMP-9-
modiﬁed IL-8 molecule is more potent in pro-
moting cell activation (20). Our ﬁndings showing
a positive correlation between IL-8 and MMP-9
and TIMP-1, and between sputum eosinophils
and MMP-9 and TIMP-1, suggest that remodel-
ing mediators may be released simultaneously
with inﬂammatory mediators other than consec-
utively in asthmatic children. Moreover, the
presence of a link between these two events
together with the identiﬁcation of a sub-popula-
tion of MA with high sputum concentrations of
IL-8 which undergoes a higher number of exac-
erbations during the follow-up suggest that,
despite regular treatment, some patients are not
controlled in terms of both bronchial inﬂamma-
tion and disease management. The data generated
here provide new information for the identiﬁca-
tion of these speciﬁc phenotypes of MA.
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In both adults and children with moderate to
severe asthma, it has been demonstrated a
persistent activation of NF-jB system due to
an over-expression of p65 subunits and to an
increased p65-DNA complex formation (6, 21).
We provide evidences that the percentage of
sputum cells with a p65 nuclear localization is
higher in children with IA and MA than in C
at both visits 1 and 3, accordingly with IL-8,
MMP-9 and TIMP-1 sputum levels. Moreover,
the persistence of the activation of NF-jB
pathway in the two groups of asthmatic chil-
dren, supports the concept that, despite the
ongoing ICS therapy, some patients display not
completely inhibited molecular mechanisms of
airway inﬂammation. These results conﬁrm and
extend some previous observations by our
group obtained, at systemic level, in moderate
persistent asthmatic children (6). Although we
did not identify any correlations between p65
and IL-8, MMP-9 and TIMP-1, the increased
p65 nuclear localization in sputum cells sug-
gests that the activation of NF-jB system
sustains the ongoing production of pro-inﬂam-
matory and remodeling mediators also in the
airways of these asthmatic children, as previ-
ously demonstrated in adults (21).
The use of FeNO measurement and the
performance of induced sputum allows to longi-
tudinally assess bronchial inﬂammation in asth-
matic children and to investigate whether the
detection of some biomarkers could provide
additional information useful in the control
and management of the disease. Our ﬁndings
demonstrating that the number of sputum
eosinophils and IL-8 sputum concentrations in
IA and MA, correlate with the number of total
exacerbations (mild and severe exacerbations)
occurred during the follow-up suggest that these
inﬂammatory markers are associated with the
disease activity. In addition, in MA, we found
that FeNO, eosinophilia, and IL-8 levels signif-
icantly correlate with the number of severe
exacerbations, indicating the presence of a sub-
clinical inﬂammation leading to a lack of disease
control. According to the levels of these three
biomarkers two diﬀerent subgroups of MA can
be identiﬁed: the frequent (>2/yr) and the
infrequent (0 or <2/yr) exacerbators. It was
already shown, in adults, that a strategy based
on the measurement of FeNO or on sputum
eosinophils permitted to avoid asthma exacer-
bations and to reduce inhaled GC requirement
(11, 12). The ﬁndings that the frequent exacer-
bators show increased FeNO levels, sputum
eosinophilia and increased IL-8 sputum levels
extend these previous observations to a pediatric
population and further support the link between
these markers of inﬂammation and asthma
control and the occurrence of severe exacer-
bations. Similar results were obtained by
Pijnenburg et al. showing that FeNO is an early
predicting marker of relapse in asthma after
cessation of ICS (46). According to this concept,
we observed in MA a positive correlation
between IL-8 sputum concentrations and asthma
duration. Furthermore, the persistent production
of IL-8 may also indicate a greater propensity of
the frequent exacerbators to develop severe
asthma (16) and to switch to a neutrophilic
inﬂammation which is often associated with this
asthma phenotype (47).
In this study, the markers of inﬂammation (i.e.
FeNO, sputum eosinophilia and IL-8) correlate
with inﬂammation-related events, such as asthma
exacerbations, while the markers of remodeling
do not. These latter markers might likely mirror
a future development of the remodeling process.
In the present study, we did not ﬁnd any
diﬀerences in terms of FEV1 measurements
among the three study groups and the long-term
follow-up conﬁrmed the initial clinical assess-
ment of the children. Our ﬁnding of lack of
signiﬁcant decrease of FEV1 levels in patients
with asthma is consistent with the Bacharier
study (48) where this is also valid even in
moderate to severe asthmatic children, especially
among patients receiving asthma controller
therapy. According to this latter study, we found
that there is a gradient of decline in FEV1/FVC
among children with increased asthma severity.
These data suggest that FEV1/FVC could be
more sensitive than FEV1 for the detection of
smooth diﬀerences of asthma severity. Accord-
ingly, in MA we found an inverse correlation
between FEV1/FVC and asthma duration, and
between FEV1/FVC and IL-8 sputum concen-
trations.
The present study supports the importance to
monitor bronchial inﬂammation to better con-
trol asthma in children. We have previously
demonstrated that PBMC from some IA chil-
dren, as well as PBMC from some MA children,
were able to release inﬂammatory cytokines
ex vivo. In particular, we showed that moderate
asthmatic children can be diﬀerentiated into two
subgroups according to biologic and clinical
parameters, including IL-8 and GM-CSF
released by PBMC, and that these markers could
be useful to asses the clinical heterogeneity and
the control of asthma in children (6). The use of
non-invasive procedures allowed us to increase
and extend these previous ﬁndings by investiga-
ting the local bronchial inﬂammation and by
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evaluating some molecular mechanisms involved
in the persistence of inﬂammation in induced
sputum cells.
In conclusion, although the relatively small
number of recruited subjects precludes from
deﬁnitive conclusions on the clinical usefulness
of these markers, this study shows that in
moderate asthmatic children the inﬂammatory
process is associated with biologic and clini-
cal heterogeneity of the disease, despite regu-
lar glucocorticoid treatment. The association
between pro-inﬂammatory and pro-remodeling
mediators, could sustain the persistence of
inﬂammation and probably promote the lack of
disease control in a subgroup of moderate
asthmatics. This study also proposes the need
to perform large prospective studies to conﬁrm
the importance of measuring speciﬁc biomarkers
in induced sputum, concomitantly to FeNO
analyses, to assess airway inﬂammation, asthma
control, and predictivity of exacerbations in
children with asthma.
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